Q-omics provides the consensus-scored UST profile across patient tissues and cancer cell-line models. UST expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, UST is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, UST RNA expression shows 19,728 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, LUAD, and UVM as cancer lineages where UST shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UST — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UST survival associations across molecular data types. UST RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UST RNA expression–survival associations across cancer types. High UST expression shows unfavorable associations in UCEC, ACC, KIRP, LAML and HNSC, but favorable associations in LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for UST RNA expression.
This table summarizes UST tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for UST. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UST shows lower tumor expression in LUAD, KIRC, THCA, UCEC and COAD and higher tumor expression in HNSC. The LUAD box plot shows higher UST RNA expression in normal versus tumor tissue (log2 FC = −1.864, t-test p < 0.001).
This table shows molecular features associated with UST in patient tissues and cancer cell lines. In patient samples, UST shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UST RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
